Q1 FY27 Results: Revenue up 9 percent, PAT up 22 percent, cash at Rs 1,700 Mn

EBITDA margin expansionResults View source PDF Explain this filing

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.1%Reaction day

₹230.00

prior close

₹238.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%+1.7% vs market

Pharmaceuticals peers, median of 162sector-0.8%+1.9% vs sector

On the reaction day the stock moved 1.7 pts more than Nifty Microcap 250 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+8.3

10m

+6.8

15m

+9.5

30m

+6.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.1-0.6+1.7-0.8+1.9

Next day

+0.1+0.5-0.4-0.5+0.6

+2.6+1.9+0.8+0.2+2.4

+2.6+2.3+0.3+0.1+2.5

+4.3+3.6+0.7+0.5+3.9

+3.0+4.0-0.9+0.4+2.6

+1.7+4.0-2.2+1.4+0.3

15d

+1.2+4.9-3.6+0.3+0.9

+4.9+5.9-1.0+1.6+3.3

+3.2+4.8-1.6+2.7+0.5

-6.5pendingpending-2.4-4.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jagsonpal Pharmaceuticals posted Q1 FY27 revenue of Rs 822 Mn, up 8.8 percent YoY. Operating EBITDA rose 21.4 percent YoY to Rs 191 Mn, with margin expanding 241 basis points to 23.2 percent. PAT grew 22.2 percent YoY to Rs 132 Mn at 16.0 percent margin. Cash balance stood strong at Rs 1,700 Mn even after a Rs 400 Mn buyback. Company also completed 85 percent acquisition of Aequitas Healthcare for Rs 20.8 Cr to enter hospital supplies.

Likely market impact

Strong margin expansion and cash-rich balance sheet support growth. Aequitas acquisition adds hospital channel access for future revenue and profits.